99.8% Purity Pharmaceutical Raw Osimertinib Powder Azd9291 Mesylate for Lung Cancer 1421373-66-1

Posted on October 26, 2018

Model NO.: Azd9291

Trademark: XXJLHGH

Transport Package: Silver Foil Bag

Specification: 1kg

Origin: China

HS Code: 3913900000

Model NO.: Azd9291

Trademark: XXJLHGH

Transport Package: Silver Foil Bag

Specification: 1kg

Origin: China

HS Code: 3913900000
99.8% Purity Pharmaceutical Raw Osimertinib Powder Azd9291 Mesylate for Lung Cancer 1421373-66-1

1. AZD-9291 Details:
Name:AZD-9291
Synonyms:N(2{[2(diMethylaMino)ethyl](Methyl)aMino}4Methoxy5{[4(1Methyl1Hindol3yl)pyriMidin2yl]aMino}phenyl)prop2enaMide;
N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide;AZD9291;
CAS:1421373-65-0Â
MF:C28H33N7O2Â
MW:499.61Â
Feature:Orally bioavailable mutant-selective EGFR inhibitor that has been tested in Phase III clinical trials for treatment of Non-Small Cell Lung Cancer.

2. AZD-9291 Usage:
Cell lines.
Human lung cancer cells with EGFR-mutations or wild type EGFR stable expression

Preparation method
The solubility of this compound in DMSO is >10 mM. General tips for obtaining aÂ higher concentration: Please warm the tube at 37 Â°C for 10 minutes and/or shake it in the ultrasonic bath for aÂ while.Stock solution can be stored below -20Â°C for several months.
Â
3. AZD-9291 Application:
AZD9291 administered once daily orally at 5Â mg/kg caused profound regression of tumours across EGFRm+ (PC9; 178% growth inhibition) and EGFRm+/T790M (H1975; 119% growth inhibition) tumour models in vivo,after 14 days dosing. Furthermore 5Â mg/kg AZD9291 was sufficient to cause significant shrinkage of EGFRm+ and EGFRm+/T790M transgenic mouse lung tumours. Tumour growth inhibition was associated with profound inhibition of EGFR phosphorylation and key downstream signaling pathways such as AKT and ERK. Chronic long-term treatment of PC9 and H1975 xenograft tumours with AZD9291 led to aÂ complete and sustained macroscopic response, with no visible tumours after 40 days dosing, and being maintained beyond 100 days. Furthermore, pre-clinical data also indicates that AZD9291 could target tumours that have acquired resistance to the more recently identified HER2-amplification mechanism, thus potentially extending its benefit in TKI resistant patients.

Â 99.8% Purity Pharmaceutical Raw Osimertinib Powder Azd9291 Mesylate for Lung Cancer 1421373-66-1

1. AZD-9291 Details:
Name:AZD-9291
Synonyms:N(2{[2(diMethylaMino)ethyl](Methyl)aMino}4Methoxy5{[4(1Methyl1Hindol3yl)pyriMidin2yl]aMino}phenyl)prop2enaMide;
N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide;AZD9291;
CAS:1421373-65-0Â
MF:C28H33N7O2Â
MW:499.61Â
Feature:Orally bioavailable mutant-selective EGFR inhibitor that has been tested in Phase III clinical trials for treatment of Non-Small Cell Lung Cancer.

2. AZD-9291 Usage:
Cell lines.
Human lung cancer cells with EGFR-mutations or wild type EGFR stable expression

Preparation method
The solubility of this compound in DMSO is >10 mM. General tips for obtaining aÂ higher concentration: Please warm the tube at 37 Â°C for 10 minutes and/or shake it in the ultrasonic bath for aÂ while.Stock solution can be stored below -20Â°C for several months.
Â
3. AZD-9291 Application:
AZD9291 administered once daily orally at 5Â mg/kg caused profound regression of tumours across EGFRm+ (PC9; 178% growth inhibition) and EGFRm+/T790M (H1975; 119% growth inhibition) tumour models in vivo,after 14 days dosing. Furthermore 5Â mg/kg AZD9291 was sufficient to cause significant shrinkage of EGFRm+ and EGFRm+/T790M transgenic mouse lung tumours. Tumour growth inhibition was associated with profound inhibition of EGFR phosphorylation and key downstream signaling pathways such as AKT and ERK. Chronic long-term treatment of PC9 and H1975 xenograft tumours with AZD9291 led to aÂ complete and sustained macroscopic response, with no visible tumours after 40 days dosing, and being maintained beyond 100 days. Furthermore, pre-clinical data also indicates that AZD9291 could target tumours that have acquired resistance to the more recently identified HER2-amplification mechanism, thus potentially extending its benefit in TKI resistant patients.

Â